Effectiveness of defibrotide for prophylaxis of deep venous thrombosis after general surgery: A double-blind, placebo-controlled clinical trial

E. Mozzi, D. Chiurazzi, R. Germiniani, F. Pacini

Research output: Contribution to journalArticle

Abstract

The prophylactic activity of defibrotide, a new extractive antithrombotic-thrombolytic agent of mammalian origin, was assessed by detection of deep venous thrombosis (DVT) in patients who underwent general elective surgery. 120 patients (aged 25-85 years, mean 55.6) were randomly assigned to defibrotide (60 patients) or to placebo (60 patients). The two groups were homogeneous for age, sex and risk factors for DVT. The active drug was given intravenously 200 mg four times a day, starting the day before the operation and then for the following 7 days. To detect DVT, 125I-fibrinogen was used, by conventional methods. Defibrotide reduced the frequency of DVT to 4/60 (7%) from 16/60 (27%) in the placebo group. The difference was highly significant (p <0.01). Neither side effects nor anticoagulant activity were observed. On the basis of this evidence, defibrotide may be considered an effective and well-tolerated drug for prevention of DVT.

Original languageEnglish
Pages (from-to)36-38
Number of pages3
JournalPathophysiology of Haemostasis and Thrombosis
Volume16
DOIs
Publication statusPublished - 1986

Fingerprint

Controlled Clinical Trials
Venous Thrombosis
Placebos
Fibrinolytic Agents
Sex Factors
Age Factors
Pharmaceutical Preparations
Anticoagulants
Fibrinogen
defibrotide

Keywords

  • <sup>125</sup>I-fibrinogen uptake test
  • Antithrombotic activity
  • Deep venous thrombosis
  • Defibrolidc
  • Thrombolytic activity

ASJC Scopus subject areas

  • Hematology
  • Physiology (medical)

Cite this

Effectiveness of defibrotide for prophylaxis of deep venous thrombosis after general surgery : A double-blind, placebo-controlled clinical trial. / Mozzi, E.; Chiurazzi, D.; Germiniani, R.; Pacini, F.

In: Pathophysiology of Haemostasis and Thrombosis, Vol. 16, 1986, p. 36-38.

Research output: Contribution to journalArticle

@article{bab4e6b76a75497b8e1ec8a7a75f44c3,
title = "Effectiveness of defibrotide for prophylaxis of deep venous thrombosis after general surgery: A double-blind, placebo-controlled clinical trial",
abstract = "The prophylactic activity of defibrotide, a new extractive antithrombotic-thrombolytic agent of mammalian origin, was assessed by detection of deep venous thrombosis (DVT) in patients who underwent general elective surgery. 120 patients (aged 25-85 years, mean 55.6) were randomly assigned to defibrotide (60 patients) or to placebo (60 patients). The two groups were homogeneous for age, sex and risk factors for DVT. The active drug was given intravenously 200 mg four times a day, starting the day before the operation and then for the following 7 days. To detect DVT, 125I-fibrinogen was used, by conventional methods. Defibrotide reduced the frequency of DVT to 4/60 (7{\%}) from 16/60 (27{\%}) in the placebo group. The difference was highly significant (p <0.01). Neither side effects nor anticoagulant activity were observed. On the basis of this evidence, defibrotide may be considered an effective and well-tolerated drug for prevention of DVT.",
keywords = "<sup>125</sup>I-fibrinogen uptake test, Antithrombotic activity, Deep venous thrombosis, Defibrolidc, Thrombolytic activity",
author = "E. Mozzi and D. Chiurazzi and R. Germiniani and F. Pacini",
year = "1986",
doi = "10.1159/000215338",
language = "English",
volume = "16",
pages = "36--38",
journal = "Pathophysiology of Haemostasis and Thrombosis",
issn = "1424-8832",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Effectiveness of defibrotide for prophylaxis of deep venous thrombosis after general surgery

T2 - A double-blind, placebo-controlled clinical trial

AU - Mozzi, E.

AU - Chiurazzi, D.

AU - Germiniani, R.

AU - Pacini, F.

PY - 1986

Y1 - 1986

N2 - The prophylactic activity of defibrotide, a new extractive antithrombotic-thrombolytic agent of mammalian origin, was assessed by detection of deep venous thrombosis (DVT) in patients who underwent general elective surgery. 120 patients (aged 25-85 years, mean 55.6) were randomly assigned to defibrotide (60 patients) or to placebo (60 patients). The two groups were homogeneous for age, sex and risk factors for DVT. The active drug was given intravenously 200 mg four times a day, starting the day before the operation and then for the following 7 days. To detect DVT, 125I-fibrinogen was used, by conventional methods. Defibrotide reduced the frequency of DVT to 4/60 (7%) from 16/60 (27%) in the placebo group. The difference was highly significant (p <0.01). Neither side effects nor anticoagulant activity were observed. On the basis of this evidence, defibrotide may be considered an effective and well-tolerated drug for prevention of DVT.

AB - The prophylactic activity of defibrotide, a new extractive antithrombotic-thrombolytic agent of mammalian origin, was assessed by detection of deep venous thrombosis (DVT) in patients who underwent general elective surgery. 120 patients (aged 25-85 years, mean 55.6) were randomly assigned to defibrotide (60 patients) or to placebo (60 patients). The two groups were homogeneous for age, sex and risk factors for DVT. The active drug was given intravenously 200 mg four times a day, starting the day before the operation and then for the following 7 days. To detect DVT, 125I-fibrinogen was used, by conventional methods. Defibrotide reduced the frequency of DVT to 4/60 (7%) from 16/60 (27%) in the placebo group. The difference was highly significant (p <0.01). Neither side effects nor anticoagulant activity were observed. On the basis of this evidence, defibrotide may be considered an effective and well-tolerated drug for prevention of DVT.

KW - <sup>125</sup>I-fibrinogen uptake test

KW - Antithrombotic activity

KW - Deep venous thrombosis

KW - Defibrolidc

KW - Thrombolytic activity

UR - http://www.scopus.com/inward/record.url?scp=0022875830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022875830&partnerID=8YFLogxK

U2 - 10.1159/000215338

DO - 10.1159/000215338

M3 - Article

C2 - 3519382

AN - SCOPUS:0022875830

VL - 16

SP - 36

EP - 38

JO - Pathophysiology of Haemostasis and Thrombosis

JF - Pathophysiology of Haemostasis and Thrombosis

SN - 1424-8832

ER -